(Reuters) – Foghorn Therapeutics Inc said on Monday it has paused enrollment in an early-stage study of the company’s experimental cancer drug due to safety concerns.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Devika Syamnath)
Foghorn Therapeutics pauses enrollment in cancer study
Apr 24, 2023 | 7:13 AM
